Crestwood Advisors Group LLC Has $31.71 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Crestwood Advisors Group LLC cut its position in Kenvue Inc. (NYSE:KVUE) by 0.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,485,122 shares of the company’s stock after selling 3,982 shares during the period. Crestwood Advisors Group LLC owned 0.08% of Kenvue worth $31,707,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. AMF Tjanstepension AB grew its position in Kenvue by 187.3% in the 3rd quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock valued at $2,787,000 after purchasing an additional 78,540 shares during the period. Sequoia Financial Advisors LLC increased its position in shares of Kenvue by 6.2% during the third quarter. Sequoia Financial Advisors LLC now owns 24,690 shares of the company’s stock worth $571,000 after acquiring an additional 1,449 shares in the last quarter. Signaturefd LLC increased its position in shares of Kenvue by 394.0% during the third quarter. Signaturefd LLC now owns 4,061 shares of the company’s stock worth $94,000 after acquiring an additional 3,239 shares in the last quarter. International Assets Investment Management LLC increased its position in shares of Kenvue by 1,529.5% during the third quarter. International Assets Investment Management LLC now owns 106,341 shares of the company’s stock worth $2,460,000 after acquiring an additional 99,815 shares in the last quarter. Finally, Allworth Financial LP increased its position in shares of Kenvue by 5.9% during the third quarter. Allworth Financial LP now owns 20,023 shares of the company’s stock worth $463,000 after acquiring an additional 1,113 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 4.1 %

Kenvue stock opened at $23.31 on Monday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The firm has a 50 day moving average price of $21.31 and a 200-day moving average price of $22.20. The company has a market capitalization of $44.68 billion, a P/E ratio of 43.97, a P/E/G ratio of 2.62 and a beta of 1.45. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.52%. Kenvue’s dividend payout ratio is presently 154.72%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Barclays decreased their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Citigroup decreased their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and reduced their target price for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Canaccord Genuity Group reduced their target price on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.